Previous 10 | Next 10 |
Annovis Bio, Inc. (NYSE:ANVS) -53% after presenting Alzheimer's drug data at AAIC 2021. Atreca, Inc. (NASDAQ:BCEL) -29% after presents initial clinical data from Phase 1b trial of ATRC-101 in select advanced solid tumors. Citrix Systems, Inc. (NASDAQ:CTXS) -16% on Q2 ...
Annovis Bio (NYSE:ANVS) plunges 49.3% premarket after announcing new clinical efficacy and biomarker data of its drug ANVS401 at the 2021 Alzheimer's Association International Conference (AAIC). ANVS401 reverses the toxic cascade, starting with lowering the levels of neurotoxic prot...
Berwyn, Pennsylvania--(Newsfile Corp. - July 28, 2021) - Annovis Bio, Inc. (NYSE American: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, with data from two phase 2 s...
There are no Alzheimer's modifying therapies on market for one of the world's greatest challenges - aducanumab does not look like the answer. Cassava's simufilam has a unique approach and highly differentiated data. Impending nine-month data could be simufilam's coming out party. ...
knowlesgallery/iStock via Getty Images The Alzheimer's Association International Conference begins Monday and runs through July 30 both in person in Denver and online. As always, there are several eagerly awaited presentations from companies working on Alzheimer's therapies that could lead to...
Shares of Annovis Bio Inc. (NYSE American:ANVS) traded today at $132.00, eclipsing its 52-week high. Approximately 593,000 shares have changed hands today, as compared to an average 30-day volume of 707,000 shares. Annovis Bio Inc is a clinical stage pharmaceutical company focused on dev...
Biotech stocks had a muted first half with the S&P Biotech Index down year-to-date, and more than 20% lower from its mid-February peak. The decline in biotech stocks coincided with a spike in interest rates and stabilizing interest rates can provide a boost to valuations. M&am...
Socket Mobile SCKT +79% on Q2 earningsAlzamend Neuro ALZN +62% after data showing safety of Alzheimer’s therapy in mouse studyVeoneer VNE +55% on earningsAcorda Therapeutics ACOR+49% on INBRIJA distribution and supply dealNRx Pharmaceuticals (NRXP) +5...
New efficacy and biomarker data to be featured in panel presentation on Wednesday, July 28. A poster presentation featuring positive clinical outcome data from the Company's two Phase 2a studies will be available on Monday, July 26 Berwyn, Pennsylvania--(Newsfile Corp. - July 23, 2021) - Anno...
Safety and tolerability data for Cohort 2 of the Discover Study reviewed by Data Safety Monitoring Board, allowing the study to proceed with the final cohort Berwyn, Pennsylvania--(Newsfile Corp. - July 20, 2021) - Annovis Bio, Inc. (NYSE American: ANVS), ("Annovis" or the "Company"), a clini...
News, Short Squeeze, Breakout and More Instantly...
Annovis Bio (NYSE: ANVS) , a late-stage, drug-platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s (“AD”) and Parkinson’s disease (“PD”), today announced the receipt of U.S. Patent No. 12,042,482. The patent ...
MALVERN, Pa., July 24, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’...
The new executive team includes Mark White, Alexander Morin, Hilda Maibach, and Blake Jensen These additions are pivotal as the company makes strides toward bringing flagship drug candidate buntanetap closer to New Drug Application (“NDA”) status and to market Annovis Bio (NYS...